Qiagen N.V. (QGEN) to Distribute Annual Dividend of $0.35 on July 14th

Qiagen N.V. (NYSE:QGEN) announced an annual dividend on Monday, May 11th. Shareholders of record on Tuesday, July 7th will be paid a dividend of 0.35 per share on Tuesday, July 14th. This represents a yield of 104.0%. The ex-dividend date is Tuesday, July 7th. This is a 33.0% increase from Qiagen’s previous annual dividend of $0.26.

Qiagen has a payout ratio of 13.9% meaning its dividend is sufficiently covered by earnings. Analysts expect Qiagen to earn $2.63 per share next year, which means the company should continue to be able to cover its $0.35 annual dividend with an expected future payout ratio of 13.3%.

Qiagen Price Performance

QGEN opened at $40.08 on Friday. The stock has a fifty day moving average of $36.24 and a 200-day moving average of $42.87. The firm has a market capitalization of $8.26 billion, a P/E ratio of 20.93, a PEG ratio of 4.00 and a beta of 0.64. Qiagen has a 12-month low of $32.53 and a 12-month high of $57.81. The company has a quick ratio of 2.57, a current ratio of 3.21 and a debt-to-equity ratio of 0.49.

Qiagen (NYSE:QGEN) last issued its earnings results on Thursday, May 7th. The company reported $0.54 EPS for the quarter, hitting the consensus estimate of $0.54. The business had revenue of $492.32 million during the quarter, compared to analysts’ expectations of $496.15 million. Qiagen had a return on equity of 14.40% and a net margin of 19.16%.During the same quarter last year, the firm posted $0.56 earnings per share. Equities analysts forecast that Qiagen will post 2.43 EPS for the current fiscal year.

Qiagen Company Profile

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.